REFERENCES
1. Bione S, D’Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D. A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet. 1996;12:385-9.
2. Neuwald AF. Barth syndrome may be due to an acyltransferase deficiency. Curr Biol. 1997;7:R465-6.
3. Barth PG, Scholte HR, Berden JA, et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J Neurol Sci. 1983;62:327-55.
4. Bissler JJ, Tsoras M, Göring HH, et al. Infantile dilated X-linked cardiomyopathy, G4.5 mutations, altered lipids, and ultrastructural malformations of mitochondria in heart, liver, and skeletal muscle. Lab Invest. 2002;82:335-44.
5. Roberts AE, Nixon C, Steward CG, et al. The Barth syndrome registry: distinguishing disease characteristics and growth data from a longitudinal study. Am J Med Genet A. 2012;158A:2726-32.
6. Garlid AO, Schaffer CT, Kim J, Bhatt H, Guevara-Gonzalez V, Ping P. TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome. Gene. 2020;726:144148.
7. Taylor C, Rao ES, Pierre G, et al. Clinical presentation and natural history of Barth syndrome: an overview. J Inherit Metab Dis. 2022;45:7-16.
8. Bashir A, Bohnert KL, Reeds DN, et al. Impaired cardiac and skeletal muscle bioenergetics in children, adolescents, and young adults with Barth syndrome. Physiol Rep. 2017;5:e13130.
9. Spencer CT, Byrne BJ, Bryant RM, et al. Impaired cardiac reserve and severely diminished skeletal muscle O2 utilization mediate exercise intolerance in Barth syndrome. Am J Physiol Heart Circ Physiol. 2011;301:H2122-9.
10. Mazzocco MM, Henry AE, Kelly RI. Barth syndrome is associated with a cognitive phenotype. J Dev Behav Pediatr. 2007;28:22-30.
11. Cade WT, Bohnert KL, Peterson LR, et al. Blunted fat oxidation upon submaximal exercise is partially compensated by enhanced glucose metabolism in children, adolescents, and young adults with Barth syndrome. J Inherit Metab Dis. 2019;42:480-93.
12. Kenneson A, Huang Y, Lontok E, Marjoram L. The diagnostic odyssey, clinical burden, and natural history of Barth syndrome: an analysis of patient registry data. J Transl Genet Genom. 2024;8:285-98.
13. Chu XY, Xu YY, Tong XY, Wang G, Zhang HY. The legend of ATP: from origin of life to precision medicine. Metabolites. 2022;12:461.
14. Wiseman RW, Brown CM, Beck TW, et al. Creatine kinase equilibration and ΔG(ATP) over an extended range of physiological conditions: implications for cellular energetics, signaling, and muscle performance. Int J Mol Sci. 2023;24:13244.
15. Schmidt CA, Fisher-Wellman KH, Neufer PD. From OCR and ECAR to energy: perspectives on the design and interpretation of bioenergetics studies. J Biol Chem. 2021;297:101140.
16. Kushmerick MJ, Moerland TS, Wiseman RW. Mammalian skeletal muscle fibers distinguished by contents of phosphocreatine, ATP, and Pi. Proc Natl Acad Sci USA. 1992;89:7521-5.
17. Hafen PS, Law AS, Matias C, Miller SG, Brault JJ. Skeletal muscle contraction kinetics and AMPK responses are modulated by the adenine nucleotide degrading enzyme AMPD1. J Appl Physiol. 2022;133:1055-66.
18. Brault JJ, Pizzimenti NM, Dentel JN, Wiseman RW. Selective inhibition of ATPase activity during contraction alters the activation of p38 MAP kinase isoforms in skeletal muscle. J Cell Biochem. 2013;114:1445-55.
19. Hancock CR, Brault JJ, Terjung RL. Protecting the cellular energy state during contractions: role of AMP deaminase. J Physiol Pharmacol. 2006;57 Suppl 10:17-29.
20. Amorese AJ, Minchew EC, Tarpey MD, et al. Hypoxia resistance is an inherent phenotype of the mouse flexor digitorum brevis skeletal muscle. Function. 2023;4:zqad012.
21. Greiner JV, Glonek T. Intracellular ATP concentration and implication for cellular evolution. Biology. 2021;10:1166.
22. Davis PR, Miller SG, Verhoeven NA, et al. Increased AMP deaminase activity decreases ATP content and slows protein degradation in cultured skeletal muscle. Metabolism. 2020;108:154257.
23. Miller SG, Hafen PS, Law AS, et al. AMP deamination is sufficient to replicate an atrophy-like metabolic phenotype in skeletal muscle. Metabolism. 2021;123:154864.
24. Hancock EJ, Krycer JR, Ang J. Metabolic buffer analysis reveals the simultaneous, independent control of ATP and adenylate energy ratios. J R Soc Interface. 2021;18:20200976.
25. Rauckhorst AJ, Borcherding N, Pape DJ, Kraus AS, Scerbo DA, Taylor EB. Mouse tissue harvest-induced hypoxia rapidly alters the in vivo metabolome, between-genotype metabolite level differences, and 13C-tracing enrichments. Mol Metab. 2022;66:101596.
26. Goossens C, Tambay V, Raymond VA, Rousseau L, Turcotte S, Bilodeau M. Impact of the delay in cryopreservation timing during biobanking procedures on human liver tissue metabolomics. PLoS One. 2024;19:e0304405.
27. Brault JJ, Abraham KA, Terjung RL. Phosphocreatine content of freeze-clamped muscle: influence of creatine kinase inhibition. J Appl Physiol. 2003;94:1751-6.
28. Hancock CR, Brault JJ, Wiseman RW, Terjung RL, Meyer RA. 31P-NMR observation of free ADP during fatiguing, repetitive contractions of murine skeletal muscle lacking AK1. Am J Physiol Cell Physiol. 2005;288:C1298-304.
29. Marvin JS, Kokotos AC, Kumar M, et al. iATPSnFR2: a high-dynamic-range fluorescent sensor for monitoring intracellular ATP. Proc Natl Acad Sci USA. 2024;121:e2314604121.
30. Stanley PE, Williams SG. Use of the liquid scintillation spectrometer for determining adenosine triphosphate by the luciferase enzyme. Anal Biochem. 1969;29:381-92.
31. Yang NC, Ho WM, Chen YH, Hu ML. A convenient one-step extraction of cellular ATP using boiling water for the luciferin-luciferase assay of ATP. Anal Biochem. 2002;306:323-7.
32. Tullson PC, Whitlock DM, Terjung RL. Adenine nucleotide degradation in slow-twitch red muscle. Am J Physiol. 1990;258:C258-65.
33. Law AS, Hafen PS, Brault JJ. Liquid chromatography method for simultaneous quantification of ATP and its degradation products compatible with both UV-Vis and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1206:123351.
34. Schlame M, Greenberg ML. Biosynthesis, remodeling and turnover of mitochondrial cardiolipin. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862:3-7.
35. Duncan AL. Monolysocardiolipin (MLCL) interactions with mitochondrial membrane proteins. Biochem Soc Trans. 2020;48:993-1004.
36. Gonzalez-Franquesa A, Stocks B, Chubanava S, et al. Mass-spectrometry-based proteomics reveals mitochondrial supercomplexome plasticity. Cell Rep. 2021;35:109180.
37. Zhang M, Mileykovskaya E, Dowhan W. Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. J Biol Chem. 2002;277:43553-6.
38. Zhang M, Mileykovskaya E, Dowhan W. Cardiolipin is essential for organization of complexes III and IV into a supercomplex in intact yeast mitochondria. J Biol Chem. 2005;280:29403-8.
39. Claypool SM, Boontheung P, McCaffery JM, Loo JA, Koehler CM. The cardiolipin transacylase, tafazzin, associates with two distinct respiratory components providing insight into Barth syndrome. Mol Biol Cell. 2008;19:5143-55.
41. Acehan D, Vaz F, Houtkooper RH, et al. Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome. J Biol Chem. 2011;286:899-908.
42. Snider PL, Sierra Potchanant EA, Sun Z, et al. A Barth syndrome patient-derived D75H point mutation in TAFAZZIN drives progressive cardiomyopathy in mice. Int J Mol Sci. 2024;25:8201.
43. Soustek MS, Falk DJ, Mah CS, et al. Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency. Hum Gene Ther. 2011;22:865-71.
44. Suzuki-Hatano S, Saha M, Rizzo SA, et al. AAV-mediated TAZ gene replacement restores mitochondrial and cardioskeletal function in Barth syndrome. Hum Gene Ther. 2019;30:139-54.
45. Prola A, Blondelle J, Vandestienne A, et al. Cardiolipin content controls mitochondrial coupling and energetic efficiency in muscle. Sci Adv. 2021;7:eabd6322.
46. Russo S, De Rasmo D, Rossi R, Signorile A, Lobasso S. SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome. Sci Rep. 2024;14:13655.
47. Powers C, Huang Y, Strauss A, Khuchua Z. Diminished exercise capacity and mitochondrial bc1 complex deficiency in tafazzin-knockdown mice. Front Physiol. 2013;4:74.
48. Johnson JM, Ferrara PJ, Verkerke ARP, et al. Targeted overexpression of catalase to mitochondria does not prevent cardioskeletal myopathy in Barth syndrome. J Mol Cell Cardiol. 2018;121:94-102.
49. Lou W, Reynolds CA, Li Y, et al. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: a myoblast model of Barth syndrome and cardiolipin deficiency. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:857-65.
50. Petit PX, Ardilla-Osorio H, Penalvia L, Rainey NE. Tafazzin mutation affecting cardiolipin leads to increased mitochondrial superoxide anions and mitophagy inhibition in Barth syndrome. Cells. 2020;9:2333.
51. Goncalves RLS, Schlame M, Bartelt A, Brand MD, Hotamışlıgil GS. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H2O2 production in heart and skeletal muscle mitochondria. FEBS Lett. 2021;595:415-32.
52. Zhu S, Chen Z, Zhu M, et al. Cardiolipin remodeling defects impair mitochondrial architecture and function in a murine model of Barth syndrome cardiomyopathy. Circ Heart Fail. 2021;14:e008289.
53. Chowdhury A, Boshnakovska A, Aich A, et al. Metabolic switch from fatty acid oxidation to glycolysis in knock-in mouse model of Barth syndrome. EMBO Mol Med. 2023;15:e17399.
54. Pacak CA, Suzuki-Hatano S, Khadir F, et al. One episode of low intensity aerobic exercise prior to systemic AAV9 administration augments transgene delivery to the heart and skeletal muscle. J Transl Med. 2023;21:748.
55. Liang Z, Ralph-Epps T, Schmidtke MW, et al. Upregulation of the AMPK-FOXO1-PDK4 pathway is a primary mechanism of pyruvate dehydrogenase activity reduction in tafazzin-deficient cells. Sci Rep. 2024;14:11497.
56. Ferrara PJ, Lang MJ, Johnson JM, et al. Weight loss increases skeletal muscle mitochondrial energy efficiency in obese mice. Life Metab. 2023;2:load014.
57. Dudek J, Cheng IF, Chowdhury A, et al. Cardiac-specific succinate dehydrogenase deficiency in Barth syndrome. EMBO Mol Med. 2016;8:139-54.
58. Soustek MS, Baligand C, Falk DJ, Walter GA, Lewin AS, Byrne BJ. Endurance training ameliorates complex 3 deficiency in a mouse model of Barth syndrome. J Inherit Metab Dis. 2015;38:915-22.
59. Liu X, Wang S, Guo X, et al. Increased reactive oxygen species-mediated Ca2+/calmodulin-dependent protein kinase II activation contributes to calcium handling abnormalities and impaired contraction in Barth syndrome. Circulation. 2021;143:1894-911.
60. He Q, Harris N, Ren J, Han X. Mitochondria-targeted antioxidant prevents cardiac dysfunction induced by tafazzin gene knockdown in cardiac myocytes. Oxid Med Cell Longev. 2014;2014:654198.
61. Greenwell AA, Tabatabaei Dakhili SA, Ussher JR. Myocardial disturbances of intermediary metabolism in Barth syndrome. Front Cardiovasc Med. 2022;9:981972.
62. Milon L, Meyer P, Chiadmi M, et al. The human nm23-H4 gene product is a mitochondrial nucleoside diphosphate kinase. J Biol Chem. 2000;275:14264-72.
63. Tokarska-Schlattner M, Boissan M, Munier A, et al. The nucleoside diphosphate kinase D (NM23-H4) binds the inner mitochondrial membrane with high affinity to cardiolipin and couples nucleotide transfer with respiration. J Biol Chem. 2008;283:26198-207.
64. Meyer RA, Sweeney HL, Kushmerick MJ. A simple analysis of the “phosphocreatine shuttle”. Am J Physiol. 1984;246:C365-77.
65. Schlattner U, Gehring F, Vernoux N, et al. C-terminal lysines determine phospholipid interaction of sarcomeric mitochondrial creatine kinase. J Biol Chem. 2004;279:24334-42.
66. Schlattner U, Tokarska-Schlattner M, Ramirez S, et al. Dual function of mitochondrial Nm23-H4 protein in phosphotransfer and intermembrane lipid transfer: a cardiolipin-dependent switch. J Biol Chem. 2013;288:111-21.
67. Schlattner U, Tokarska-Schlattner M, Rousseau D, et al. Mitochondrial cardiolipin/phospholipid trafficking: the role of membrane contact site complexes and lipid transfer proteins. Chem Phys Lipids. 2014;179:32-41.
68. Gonzalvez F, D’Aurelio M, Boutant M, et al. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation. Biochim Biophys Acta. 2013;1832:1194-206.
69. Aryal B, Rao VA. Deficiency in cardiolipin reduces doxorubicin-induced oxidative stress and mitochondrial damage in human B-lymphocytes. PLoS One. 2016;11:e0158376.
70. Wang G, McCain ML, Yang L, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 2014;20:616-23.
71. He Q. Tafazzin knockdown causes hypertrophy of neonatal ventricular myocytes. Am J Physiol Heart Circ Physiol. 2010;299:H210-6.
72. He Q, Wang M, Harris N, Han X. Tafazzin knockdown interrupts cell cycle progression in cultured neonatal ventricular fibroblasts. Am J Physiol Heart Circ Physiol. 2013;305:H1332-43.
73. Suzuki-Hatano S, Sriramvenugopal M, Ramanathan M, et al. Increased mtDNA abundance and improved function in human Barth syndrome patient fibroblasts following AAV-TAZ gene delivery. Int J Mol Sci. 2019;20:3416.
74. Gürtler S, Wolke C, Otto O, et al. Tafazzin-dependent cardiolipin composition in C6 glioma cells correlates with changes in mitochondrial and cellular functions, and cellular proliferation. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:452-65.
75. Rua AJ, Mitchell W, Claypool SM, Alder NN, Alexandrescu AT. Perturbations in mitochondrial metabolism associated with defective cardiolipin biosynthesis: an in-organello real-time NMR study. J Biol Chem. 2024;300:107746.
76. Huang Y, Powers C, Madala SK, et al. Cardiac metabolic pathways affected in the mouse model of Barth syndrome. PLoS One. 2015;10:e0128561.
77. Wang S, Li Y, Xu Y, et al. AAV gene therapy prevents and reverses heart failure in a murine knockout model of Barth syndrome. Circ Res. 2020;126:1024-39.
78. Snider PL, Sierra Potchanant EA, Matias C, Edwards DM, Brault JJ, Conway SJ. The loss of tafazzin Transacetylase activity is sufficient to drive testicular infertility. J Dev Biol. 2024;12:32.
79. Chen Z, Zhu S, Wang H, et al. PTPMT1 is required for embryonic cardiac cardiolipin biosynthesis to regulate mitochondrial morphogenesis and heart development. Circulation. 2021;144:403-6.
81. Cade WT, Laforest R, Bohnert KL, et al. Myocardial glucose and fatty acid metabolism is altered and associated with lower cardiac function in young adults with Barth syndrome. J Nucl Cardiol. 2021;28:1649-59.
82. Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23:471-8.
83. Roshanravan B, Liu SZ, Ali AS, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021;16:e0253849.
84. Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90:e1212-21.
85. Verma M, Francis L, Lizama BN, et al. iPSC-derived neurons from patients with POLG mutations exhibit decreased mitochondrial content and dendrite simplification. Am J Pathol. 2023;193:201-12.
86. Löfberg M, Lindholm H, Näveri H, et al. ATP, phosphocreatine and lactate in exercising muscle in mitochondrial disease and McArdle’s disease. Neuromuscul Disord. 2001;11:370-5.
87. Lancaster MS, Hafen P, Law AS, et al. Sucla2 knock-out in skeletal muscle yields mouse model of mitochondrial myopathy with muscle type-specific phenotypes. J Cachexia Sarcopenia Muscle. 2024;15:2729-42.
